Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185185
Status:
COMPLETED
Last Update Posted:
2007-12-14
First Post:
2005-09-12
Brief Title:
Olmesartan Medoxomil in Atherosclerosis
Sponsor:
Sankyo Pharma Gmbh
Organization:
Daiichi Sankyo
Study Overview
Official Title:
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation MORE
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk The efficacy of olmesartan medoxomil on atherosclerosis is measured
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None